ScholarIQanswers from OpenAlex & ORCID
Hye Ryun Kim
ResearcherPublications, citations & collaboration network
Hye Ryun Kim is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hye Ryun Kim have?
ScholarIQindexed works
Hye Ryun Kim has 749 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hye Ryun Kim have?
ScholarIQcitation count
Hye Ryun Kim has 18,255 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hye Ryun Kim?
ScholarIQh-index
Hye Ryun Kim has an h-index of 61 in OpenAlex.
What is the i10-index of Hye Ryun Kim?
ScholarIQi10-index
Hye Ryun Kim has an i10-index of 232 in OpenAlex.
What is the ORCID of Hye Ryun Kim?
ScholarIQorcid
The ORCID for Hye Ryun Kim is on the source record.
What is the OpenAlex record for Hye Ryun Kim?
ScholarIQopenalex
The OpenAlex for Hye Ryun Kim is on the source record.
What are the most-cited papers on Hye Ryun Kim?
ScholarIQmost cited works
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Hye Ryun Kim, Suresh S. Ramalingam, Frances A. Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Chee Khoon Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou
Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee‐Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Angelo Delmonte, Rosario García Campelo, Dong‐Wan Kim, Alessandra Bearz, Frank Griesinger, Alessandro Morabito, Enriqueta Felip, Raffaele Califano, Sharmistha Ghosh, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Neeraj Gupta, J. Haney, David Kerstein, Sanjay Popat
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, M.R. García Campelo, Dong‐Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Huamao Mark Lin, Yuyin Liu, Florin Vranceanu, Huifeng Niu, Pingkuan Zhang, Sanjay Popat
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, M.R. García Campelo, Dong‐Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Huamao Mark Lin, Neeraj Gupta, Michael J. Hanley, Quanhong Ni, Pingkuan Zhang, Sanjay Popat
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun‐Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi, Hyo Sup Shim, Jin‐Haeng Chung, Yoon‐La Choi, Min Jeong Lee, Maria Kim, Joo-Hang Kim, Siraj M. Ali, Myung‐Ju Ahn, Byoung Chul Cho